title: Antiphospholipid syndrome and recurrent miscarriages.
abstract: Sixty percent of recurrent spontaneous abortions are unexplained. Antiphospholipid syndrome is a multisystem disease with the predominant features of venous and arterial thrombosis, recurrent pregnancy loss, foetal death and the presence of antiphospholipid antibodies. Many epidemiological studies focus on antiphospholipid autoantibodies syndrome (APS) as a cause of recurrent spontaneous abortion (RSA). It is found that 7-25% of RSA would have APS as the main risk factor. 'Association not being synonymous with cause', the proportion of abortions due to the APS is difficult to estimate for several reasons: definition of recurrent abortion is variable, the assays for antiphospholipid antibodies are not well standardised, inclusion of patients in the study group according to the antibodies titre is author dependent. Recent studies suggest association of antiphospholipid antibodies syndrome not only with recurrent abortions but also with infertility. New mechanisms are described by which antiphospholipid antibodies could cause placental thrombosis and infarction, acting directly on the surface anticoagulant expressed on trophoblastic cells. Only lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) assays are sufficiently standardised to be usable in routine. Testing for other antiphospholipid antibodies (aPLs) should remain investigational. Several treatments have been proposed: low doses of aspirin, low or immunosuppressive doses of corticosteroids, and preventive or effective dose of heparin, intravenous immunoglobulin.
authors: Hôpital Jeanne de Flandre, Clinique de Gynécologie Obstétrique et Néonatalogie, Centre Hospitalier Universitaire de Lille, F59037 Cedex, Lille, France. dvinatier@chru-lille.fr
authors: D
authors: D
authors: Vinatier
authors: P
authors: P
authors: Dufour
authors: M
authors: M
authors: Cosson
authors: J L
authors: JL
authors: Houpeau
mesh_terms: D000026:Abortion, Habitual / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000209:etiology* / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D007275:Injections, Intravenous; D016682:Lupus Coagulation Inhibitor / Q000032:analysis; D011247:Pregnancy
chemical_list: D000305:Adrenal Cortex Hormones; D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D007136:Immunoglobulins; D016682:Lupus Coagulation Inhibitor; D006493:Heparin; D001241:Aspirin